Figures computed from official regulatory filings — .
Analysttarget 10 USD (+571%)
Ownershipinsiders 8.87% · institutions 8.16% · short 1.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Silo Pharma, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
44 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Weisblum Erictrack record | Buy | $1K | conv 22 |
| Weisblum Erictrack record | Buy | $1.1K | conv 22 | SEC |
| Weisblum Erictrack record | Buy | $370 | conv 33 | SEC |
| Weisblum Erictrack record | Buy | $370 | conv 33 | SEC |
| Weisblum Erictrack record | Buy | $3K | conv 45 | SEC |
| Weisblum Erictrack record | Buy | $1.8K | conv 33 | SEC |
| Weisblum Erictrack record | Buy | $4.3K | conv 47 | SEC |
| Linsley Wayne | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pavell Jeff | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ryweck Daniel E. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Weisblum Erictrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Munoz Kevin | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Weisblum Erictrack record | Buy | $2.1K | conv 25 | SEC |
| Weisblum Erictrack record | Buy | $2.4K | conv 41 | SEC |
| Weisblum Erictrack record | Buy | $2.3K | conv 35 | SEC |
| Weisblum Erictrack record | Buy | $4.9K | conv 48 | SEC |
| Weisblum Erictrack record | Buy | $607 | conv 35 | SEC |
| Weisblum Erictrack record | Buy | $1.2K | conv 21 | SEC |
| Weisblum Erictrack record | Buy | $812 | conv 21 | SEC |
| Weisblum Erictrack record | Buy | $6.6K | conv 48Unusual size | SEC |
| Weisblum Erictrack record | Buy | $2.1K | conv 23 | SEC |
| Weisblum Erictrack record | Buy | $322 | conv 32 | SEC |
| Weisblum Erictrack record | Buy | $815 | conv 33 | SEC |
| Weisblum Erictrack record | Buy | $300 | conv 33 | SEC |
| Weisblum Erictrack record | Buy | $1.4K | conv 33 | SEC |